Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Madden, Stephen F
AffiliationNational Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland. email@example.com
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-abl
Proto-Oncogene Proteins c-kit
Receptor, Epidermal Growth Factor
Receptor, Platelet-Derived Growth Factor alpha
Receptor, Platelet-Derived Growth Factor beta
Tumor Cells, Cultured
MetadataShow full item record
CitationCharacterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib. 2012, 318 (5):641-52 Exp. Cell Res.
JournalExperimental cell research
AbstractHigh-grade gliomas (HGG), are the most common aggressive brain tumours in adults. Inhibitors targeting growth factor signalling pathways in glioma have shown a low clinical response rate. To accurately evaluate response to targeted therapies further in vitro studies are necessary. Growth factor pathway expression using epidermal growth factor receptor (EGFR), mutant EGFR (EGFRvIII), platelet derived growth factor receptor (PDGFR), C-Kit and C-Abl together with phosphatase and tensin homolog (PTEN) expression and downstream activation of AKT and phosphorylated ribosomal protein S6 (P70S6K) was analysed in 26 primary glioma cultures treated with the tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib and imatinib. Response to TKIs was assessed using 50% inhibitory concentrations (IC(50)). Response for each culture was compared with the EGFR/PDGFR immunocytochemical pathway profile using hierarchical cluster analysis (HCA) and principal component analysis (PCA). Erlotinib response was not strongly associated with high expression of the growth factor pathway components. PTEN expression did not correlate with response to any of the three TKIs. Increased EGFR expression was associated with gefitinib response; increased PDGFR-α expression was associated with imatinib response. The results of this in vitro study suggest gefitinib and imatinib may have therapeutic potential in HGG tumours with a corresponding growth factor receptor expression profile.
- Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
- Authors: Haberler C, Gelpi E, Marosi C, Rössler K, Birner P, Budka H, Hainfellner JA
- Issue date: 2006 Jan
- Comparative genomic and proteomic analysis of high grade glioma primary cultures and matched tumor in situ.
- Authors: Howley R, Kinsella P, Buckley PG, Alcock L, Jansen M, Heffernan J, Stallings RL, Brett FM, Amberger-Murphy V, Farrell MA
- Issue date: 2012 Oct 15
- Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
- Authors: Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D
- Issue date: 2005 Jun 15
- Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
- Authors: Servidei T, Riccardi A, Sanguinetti M, Dominici C, Riccardi R
- Issue date: 2006 Jul
- Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
- Authors: Matei D, Chang DD, Jeng MH
- Issue date: 2004 Jan 15